New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:18 EDTMYLMylan announces agreement with Biocon for collaboration on insulin products
Mylan (MYL) announced that it has entered into a definitive agreement with Biocon Limited for an exclusive strategic collaboration on the development and commercialization of generic versions of three insulin analog products. Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon's Glargine, the generic version of Sanofi's (SNY) Lantus, Lispro, the generic version of Eli Lilly's (LLY) Humalog, and Aspart, the generic version of Novo Nordisk's (NVO) NovoLog. Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Reported worldwide net sales of Lantus, Humalog and NovoLog for 2012 were approximately $11.5B.
News For MYL From The Last 14 Days
Check below for free stories on MYL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
04:22 EDTMYLMylan (MYL) implied volatility of 45 at upper end of index mean range
April 16, 2014
16:16 EDTMYLMylan launches first generic Ortho Evra patch
Subscribe for More Information
April 15, 2014
10:21 EDTMYLMylan announces settlement agreement for first-to-file Generess
Subscribe for More Information
10:10 EDTMYLMylan launches generic Lunesta tablets
Subscribe for More Information
08:07 EDTMYLActavis announces agreement related to Generess FE patent challenge litigation
Actavis (ACT) announced that it has entered into an agreement with Mylan (MYL) and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess. Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess® FE under its pending Abbreviated New Drug Application beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd in connection with Lupin's pending ANDA for a generic version of Generess.
08:06 EDTMYLProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Subscribe for More Information
April 11, 2014
11:50 EDTMYLStocks with call strike movement; TNA MYL
Subscribe for More Information
10:30 EDTMYLActavis and Mylan shares recommended at Bernstein
07:31 EDTMYLMylan confirms judge enforces agreement with Endo regarding generic Frova
Subscribe for More Information
April 9, 2014
05:57 EDTMYLMylan implied volatility of 47 at upper end of index mean range
April 8, 2014
07:56 EDTMYLMylan volatility elevated at 42
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use